1. Home
  2. MRUS vs NEA Comparison

MRUS vs NEA Comparison

Compare MRUS & NEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRUS
  • NEA
  • Stock Information
  • Founded
  • MRUS 2003
  • NEA 2002
  • Country
  • MRUS Netherlands
  • NEA United States
  • Employees
  • MRUS N/A
  • NEA N/A
  • Industry
  • MRUS Biotechnology: Pharmaceutical Preparations
  • NEA Finance/Investors Services
  • Sector
  • MRUS Health Care
  • NEA Finance
  • Exchange
  • MRUS Nasdaq
  • NEA Nasdaq
  • Market Cap
  • MRUS 2.9B
  • NEA 3.5B
  • IPO Year
  • MRUS 2016
  • NEA N/A
  • Fundamental
  • Price
  • MRUS $43.92
  • NEA $11.44
  • Analyst Decision
  • MRUS Strong Buy
  • NEA
  • Analyst Count
  • MRUS 12
  • NEA 0
  • Target Price
  • MRUS $87.92
  • NEA N/A
  • AVG Volume (30 Days)
  • MRUS 635.1K
  • NEA 803.4K
  • Earning Date
  • MRUS 10-31-2024
  • NEA 01-01-0001
  • Dividend Yield
  • MRUS N/A
  • NEA 4.23%
  • EPS Growth
  • MRUS N/A
  • NEA N/A
  • EPS
  • MRUS N/A
  • NEA N/A
  • Revenue
  • MRUS $35,932,000.00
  • NEA N/A
  • Revenue This Year
  • MRUS N/A
  • NEA N/A
  • Revenue Next Year
  • MRUS $57.37
  • NEA N/A
  • P/E Ratio
  • MRUS N/A
  • NEA N/A
  • Revenue Growth
  • MRUS N/A
  • NEA N/A
  • 52 Week Low
  • MRUS $24.95
  • NEA $9.20
  • 52 Week High
  • MRUS $61.61
  • NEA $11.37
  • Technical
  • Relative Strength Index (RSI)
  • MRUS 43.33
  • NEA 35.14
  • Support Level
  • MRUS $41.03
  • NEA $11.84
  • Resistance Level
  • MRUS $43.68
  • NEA $11.92
  • Average True Range (ATR)
  • MRUS 2.28
  • NEA 0.08
  • MACD
  • MRUS 0.14
  • NEA -0.05
  • Stochastic Oscillator
  • MRUS 29.61
  • NEA 6.00

About MRUS Merus N.V.

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01

Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities.

Share on Social Networks: